George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
With jam (tomorrow) AS’ favourite ;)
My wife just reminded me of something ..this "new task force on the antiviral"..does it ring a bell somewhere with you? Operation Moonshot and Condor Programme? What have they done with it? They can't even organise a proverbial ****.. what about Remdesivir..the wonder drug? Poor guys at SNG, they have a real good treatment and look at where they are?
Seriously, I hope we start selling in Europe our tests first and everything we can produce here.
PL75, with apricot jam, perhaps?
Spread em on toast
tils have a nasal spray treatment going though clinical trials currently and it looks very promising indeed.
No there's not. Get out of Avacta fantasy land
This is big news for sure. Very real chance that THE AFFIMER could be fast tracked / backed for clinical trial.
London South East
Share PricesAvacta Share PriceAvacta Regulatory NewsUpdate on Affimer® Therapy for COVID-19 Infection
Pin to quick picksAvacta Regulatory News (AVCT)
AVCT Share Price
AVCT Share
Price
AVCT Share News
AVCT Share
News
3
AVCT Share Chat
AVCT Share
Chat
631
AVCT Share Trades
AVCT Share
Trades
2,486
AVCT Live RNS
AVCT
Live RNS
3
AVCT Information Buy AVCT SharesBuy AVCT SharesAdd AVCT to WatchlistAdd AVCT to WatchlistAdd AVCT to AlertAdd AVCT to AlertAdd AVCT to myTerminalAdd AVCT to myTerminal
Share Price Information for Avacta (AVCT)
London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
244.80
Bid:
245.00
Ask:
250.00
Change:
10.80 (4.62%)
Spread: 5.00 (2.04%)Open: 271.00High: 263.50Low: 244.80Yest. Close: 234.00
AVCT Live PriceLast checked at 17:43:10
Update on Affimer® Therapy for COVID-19 Infection
Thu, 18th Jun 2020 07:00
RNS Number : 2969Q
Avacta Group PLC
18 June 2020
18 June 2020
Avacta Group plc
("Avacta" or "the Group" or "the Company")
Update on Affimer® Therapy for COVID-19 Infection
Infectivity assays carried out in collaboration with Glasgow University show that Affimer reagents prevent infection of human cells by a SARS-COV-2 model virus
Avacta Group plc (AIM: AVCT), the developer of Affimer biotherapeutics and reagents, is pleased to announce that collaborative work with the Centre for Virus Research at the University of Glasgow has shown that Affimer reagents which bind to the SARS-COV-2 virus spike protein prevent infection of human cells by a SARS-COV-2 model virus and therefore provide a potential therapy for COVID-19 infection.
Recently, Avacta reported that several of the Affimer reagents that had been generated to develop COVID-19 antigen tests inhibited the interaction between the coronavirus' spike protein and a receptor found on human cells, called ACE2, which the virus spike protein binds to as the first step in infecting cells.
Avacta has now successfully completed the initial phase of a collaboration with Professor David Bhella at the University of Glasgow showing that these "neutralising" Affimer reagents prevent a SARS-COV-2 model virus from entering human cells and therefore provide a potential therapy for COVID-19.
Affimer reagents have key benefits compared with antibodies as virus neutralising therapies: Their small size and high solubility means that a much higher concentration of Affimer molecules can be used in the drug formulation to more effectively block the spike proteins on each virus particle and better protect the patient; bispecific and trispecific Affimer neutralising therapies that bind to more than one part of the spike protein could ensure the effectiveness of the neutralising therapy even if the virus' spike prote
I don't know. Is that part of the Principle trial?
Really, one is inhaled and the other suppresses the immune system. How about Favipiravir.
Getting 2 treatments through trials and approved by the end of summer is a massive undertaking actually.
Ah well the Antiviral Task Force wont have that much to worry about then if as you say its all sorted.
They are talking about Tocilizumab and Budesonide.
There is a whole world beyond Avacta you know
Avacta has a candidate neutralising therapy. Would not be too much of a stretch to imagine that this may be progressed.
Do you really think they are talking about Avacta?
FFS it's for Tocilizumab and Budesonide. They are running trials now
Boris just mentioned in his briefing that UK will establish an 'Antivirals Taskforce' to investigate and research Antivirals to combat Covid. Avacta discussed in May 2020 and previously that Affimers work as effective Antivirals. I'm thinking we might hear more about this on Thursday. If this comes off for Avacta the target price just doubled!